Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$30.55 USD
-0.11 (-0.36%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $30.56 +0.01 (0.03%) 7:56 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNN 30.55 -0.11(-0.36%)
Will SNN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNN
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
SNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
Other News for SNN
First cases using Smith+Nephew?s new CATALYSTEM? Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
Smith & Nephew Directors Buy Shares as Fees
BlackRock International VI Fund Q2 2024 Commentary
BlackRock International Fund Q2 2024 Commentary
Barclays Sticks to Its Hold Rating for Smith & Nephew (SN)